Patient management by cyclosporine C2 monitoring: Not enough science yet to justify the practice [4]

Transplantation

Volumn 75, Issue 11, 2003, Pages 1917-1918

  Campbell, Scott B ^a   Johnson, David W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN C0; CYCLOSPORIN C2; CYCLOSPORIN DERIVATIVE; DILTIAZEM; EVEROLIMUS; KETOCONAZOLE; RAPAMYCIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; LETTER; NEPHROTOXICITY; PRIORITY JOURNAL;

COMPLEMENT C2; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 0037708553     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000065807.68596.16     Document Type: Letter

References (4)

1. Nashan B, Cole E, Levy G, et al. Clinical validation studies of Neoral C2 monitoring: A review. Transplantation 2002; 73(suppl): S3-S11.
2. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C2 monitoring: An international consensus statement. Transplantation 2002; 73(suppl): S12-S18.
3. Cole E, Midtvedt K, Johnston A, et al. Recommendations for implementation of Neoral C2 monitoring in clinical practice. Transplantation 2002; 73(suppl): S19-S22.
4. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-156.